PriceTargets.com logo

First Wave BioPharma - FWBI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $118.00
  • Forecasted Upside: 3,807.28%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.02 As of 04/16/2024 01:00 AM ET
▼ -0.25 (-7.65%)

This chart shows the closing price for FWBI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New First Wave BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FWBI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FWBI

Analyst Price Target is $118.00
▲ +3,807.28% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for First Wave BioPharma in the last 3 months. The average price target is $118.00, with a high forecast of $200.00 and a low forecast of $36.00. The average price target represents a 3,807.28% upside from the last price of $3.02.

This chart shows the closing price for FWBI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in First Wave BioPharma. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/25/2024HC WainwrightReiterated RatingNeutralLow
3/15/2024Roth MkmLower TargetBuy ➝ Buy$40.00 ➝ $36.00Low
1/3/2024Roth MkmBoost TargetBuy ➝ Buy$40.00Low
9/19/2023Roth MkmReiterated RatingBuy ➝ BuyLow
7/14/2023HC WainwrightDowngradeBuy ➝ NeutralLow
5/15/2023HC WainwrightLower Target$280.00 ➝ $200.00Low
4/5/2023HC WainwrightLower TargetBuy$360.00 ➝ $280.00Low
3/9/2023HC WainwrightReiterated RatingBuy$360.00Low
2/3/2023HC WainwrightReiterated RatingBuy$360.00Low
1/26/2023HC WainwrightReiterated RatingBuy$360.00Low
10/31/2022HC WainwrightReiterated RatingBuyLow
5/26/2022Roth CapitalLower TargetBuy$84,000.00 ➝ $37,800.00High
12/7/2021Maxim GroupDowngradeBuy ➝ HoldLow
10/1/2021Maxim GroupInitiated CoverageBuy$33,600.00Medium
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2023
  • 1 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
First Wave BioPharma logo
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Read More

Today's Range

Now: $3.02
Low: $2.97
High: $3.30

50 Day Range

MA: $5.18
Low: $3.02
High: $9.24

52 Week Range

Now: $3.02
Low: $2.75
High: $73.00

Volume

61,635 shs

Average Volume

262,777 shs

Market Capitalization

$6.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of First Wave BioPharma?

The following Wall Street analysts have issued research reports on First Wave BioPharma in the last year: HC Wainwright, and Roth Mkm.
View the latest analyst ratings for FWBI.

What is the current price target for First Wave BioPharma?

2 Wall Street analysts have set twelve-month price targets for First Wave BioPharma in the last year. Their average twelve-month price target is $118.00, suggesting a possible upside of 3,807.3%. HC Wainwright has the highest price target set, predicting FWBI will reach $200.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $36.00 for First Wave BioPharma in the next year.
View the latest price targets for FWBI.

What is the current consensus analyst rating for First Wave BioPharma?

First Wave BioPharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for FWBI.

What other companies compete with First Wave BioPharma?

Other companies that are similar to First Wave BioPharma include Lixte Biotechnology, Akari Therapeutics, Trevena, Kazia Therapeutics and Xenetic Biosciences. Learn More about companies similar to First Wave BioPharma.

How do I contact First Wave BioPharma's investor relations team?

First Wave BioPharma's physical mailing address is 760 Parkside Ave Ste 304, Brooklyn, New York 11226-1784. The company's listed phone number is (561) 589-7020 and its investor relations email address is [email protected]. The official website for First Wave BioPharma is www.azurrx.com. Learn More about contacing First Wave BioPharma investor relations.